VanderVen, Brian C <br/><br/>
Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment.  [electronic resource] 

 -  PLoS pathogens  Feb 2015 
 - e1004679 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1553-7374 
<br/><br/><label>Standard No.: </label>10.1371/journal.ppat.1004679  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenylyl Cyclases--genetics<br/>Animals<br/>Antitubercular Agents--pharmacology<br/>Bacterial Proteins--metabolism<br/>Cell Line<br/>Cholesterol--metabolism<br/>Cyclic AMP--metabolism<br/>Hydroxysteroid Dehydrogenases--antagonists & inhibitors<br/>Intracellular Space<br/>Lipid Metabolism--drug effects<br/>Macrophages--immunology<br/>Mice<br/>Microbial Sensitivity Tests<br/>Mixed Function Oxygenases--antagonists & inhibitors<br/>Mycobacterium tuberculosis--growth & development<br/>Oxo-Acid-Lyases--antagonists & inhibitors<br/>Small Molecule Libraries--pharmacology<br/>Tuberculosis, Pulmonary--drug therapy